Reviva Pharmaceuticals Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Reviva Pharmaceuticals Holdings, Inc. carries a market capitalization of 2.02M, placing it among publicly traded companies globally. Its enterprise value stands at -18.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.02M |
| Enterprise Value | -18.76M |
Share Statistics
Reviva Pharmaceuticals Holdings, Inc. currently has 12.81M shares outstanding.
| Shares Outstanding | 12.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.18 |
| P/FCF Ratio | -0.16 |
| P/OCF Ratio | -0.16 |
Financial Position
Reviva Pharmaceuticals Holdings, Inc. maintains a current ratio of 3.85, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.33, indicating moderate leverage, while an interest coverage ratio of -2,007.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.85 |
| Quick Ratio | 3.63 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -2,007.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -108.55 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 17,022.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Reviva Pharmaceuticals Holdings, Inc.'s stock has declined approximately -96.3582% over the past 52 weeks. The 50-day moving average sits at 0.70, while the 200-day moving average is 6.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.3582% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 6.22 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.93M, while operating income came in at -16.93M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -16.93M |
| Pretax Income | -16.61M |
| Net Income | -16.63M |
| EBITDA | -16.93M |
| EBIT | -16.93M |
| Earnings Per Share (EPS) | -3.79 |
Balance Sheet
Reviva Pharmaceuticals Holdings, Inc. holds 22.19M in cash and equivalents against 231,274.00 in total debt, resulting in a net debt position of -21.96M. Total book value stands at -187.32M, with working capital of 17.44M providing operational flexibility.
| Cash & Cash Equivalents | 22.19M |
| Total Debt | 231,274.00 |
| Net Debt | -21.96M |
| Equity (Book Value) | -187.32M |
| Book Value Per Share | -42.74 |
| Working Capital | 17.44M |
Cash Flow
Reviva Pharmaceuticals Holdings, Inc. produced -20.20M in operating cash flow over the past twelve months.
| Operating Cash Flow | -20.20M |
| Capital Expenditures | N/A |
| Free Cash Flow | -20.20M |
| FCF Per Share | -4.61 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,160.03 |
| FCF Yield | -631.61 |
Stock Splits
Reviva Pharmaceuticals Holdings, Inc.'s most recent stock split took place on March 9, 2026 with a 20:1 split ratio.
| Last Split Date | 3/9/2026 |
| Split Ratio | 20:1 |
Scores
Reviva Pharmaceuticals Holdings, Inc. posts an Altman Z-Score of -12.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.30 |